Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
To compare the efficacy of BF2.649 over placebo (12 week Double-Blind Phase) and assess the
long term safety and the efficacy maintenance(9 months Open-Label Extension Phase) of BF2.649
in the improvement of excessive daytime sleepiness in patients diagnosed with Parkinson's
Disease.